Public health and consumer advocacy groups are attacking Senate legislation designed to tighten oversight of specialized pharmacies such as the one at the center of this past fall’s deadly meningitis outbreak, saying it does not adequately address health risks.More info
Senior Director, Drugs and Medical Devices , The Pew Charitable Trusts
To reach this expert, please contact:Elizabeth Butler
Allan Coukell oversees medical programs, including the Pew Prescription Project, the Drug Safety Project, the Antibiotics and Innovation Project, the Medical Device Safety project and the FDA Modernization Initiative, as well as other activities related to medical products and services.
He leads the Drug Safety Project's advocacy around the need for reforms to address the risks of the global pharmaceutical manufacturing and distribution supply chain. He has also contributed to the development of federal and state legislation to foster transparency of physician-industry relationships and in the creation of programs to encourage evidence-based prescribing. He has worked closely with medical schools and medical centers developing new industry relations policies, and was co-creator of the American Medical Student Association PharmFree Scorecard, a national assessment of such policies at U.S. medical schools.
Coukell practiced as a clinical pharmacist in oncology at the Victoria Hospital and London Regional Cancer Center in London, Ontario and was subsequently a senior medical writer and editor with Adis International, publisher of the peer-reviewed journals Drugs, Drugs & Aging, and PharmacoEconomics, among others.
He also spent a decade in journalism, ultimately as health and science reporter for WBUR, Boston’s NPR news station. He was the founding producer and host of the weekly Eureka! science program on Radio New Zealand, and has written for The Economist, the New York Times, New Scientist and Discover, among other publications. He is the recipient of an Edward R Murrow award for hard news reporting.
Allan Coukell serves as the consumer representative on the FDA Cardiovascular and Renal Drugs Advisory Committee.
''A subsidiary of India's largest pharmaceutical company has agreed to pay a record $500 million in fines and penalties for selling adulterated drugs and lying to federal regulators in a case that is part of an ongoing crackdown on the quality of generic drugs flowing into the U.S."More info
The U.S. Senate Committee on Health, Education, Labor and Pensions held a hearing on May 9 entitled "Pharmaceutical Compounding: Proposed Legislative Solution." Pew's Allan Coukell, a pharmacist and drug safety expert, testified on the need to strengthen oversight of the compounding industry.More info
Pew's Allan Coukell submitted a statement of record to the Congressional Committee on Commerce, Science and Transportation regarding concerns with the pharmaceutical supply chain. The focus of Coukell's testimony was the drug distribution system – the weaknesses in the system and the risks of counterfeit and stolen drugs.More info
Show All Resources